Emerging therapies and future directions in targeting the tumor stroma and immune system in the treatment of pancreatic adenocarcinoma

Research output: Contribution to journalReview article

3 Scopus citations


Pancreatic adenocarcinoma is typically refractory to conventional treatments and associated with poor prognosis. While therapeutic advances over the past several years have improved patient outcomes, the observed benefits have been modest at best, highlighting the need for continued development of alternate treatment strategies. The tumor microenvironment has been identified as being integral to oncogenesis through its direct effect on cellular pathway communication, immune inhibition, and promoting chemo-resistance. A more in depth understanding of the biology of the disease, in addition with our ability to develop more effective novel therapies have led to ongoing studies that are investigating several promising treatment options in this disease. Herein, we highlight and review the therapeutic landscape in pancreatic adenocarcinoma.

Original languageEnglish (US)
Article number193
Issue number6
StatePublished - Jun 11 2018



  • Desmoplasia
  • Immunotherapy
  • Microenvironment
  • Novel targeted therapies
  • Pancreatic adenocarcinoma
  • Stroma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this